Candriam SCA’s Mirum Pharmaceuticals MIRM Stock Holding History

Candriam SCA’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44M	Sell	376,143 -88,073	-19%	-$8.84M	0.2%	108
2026 Q1	$42.9M	Sell	464,216 -105,374	-18%	-$9.91M	0.22%	100
2025 Q4	$45M	Buy	569,590 +166,564	+41%	+$12M	0.22%	99
2025 Q3	$29.5M	Buy	403,026 +30,021	+8%	+$1.91M	0.15%	134
2025 Q2	$19M	Sell	373,005 -9,974	-3%	-$444K	0.11%	176
2025 Q1	$17.3M	Sell	382,979 -46,752	-11%	-$2.2M	0.11%	174
2024 Q4	$17.8M	Sell	429,731 -78,744	-15%	-$3.28M	0.1%	185
2024 Q3	$19.8M	Hold	508,475	–	–	0.11%	181
2024 Q2	$17.4M	Buy	+508,475	New	+$13.3M	0.11%	192

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's MIRM Position: Q2 2026 in Review

Candriam SCA reduced its Mirum Pharmaceuticals (MIRM) stake by 19% in Q2 2026, selling an estimated $8.84M and leaving 376,143 shares worth $44M. The position accounts for 0.2% of the portfolio, ranked #108.

Candriam SCA first reported a position in MIRM in Q2 2024 and has held it in 9 quarters since. The position peaked at $45M in Q4 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Candriam SCA held 376,143 shares of Mirum Pharmaceuticals worth $44M as of Q2 2026.
Candriam SCA sold 88,073 Mirum Pharmaceuticals shares in Q2 2026, an estimated $8.84M.
Mirum Pharmaceuticals made up 0.2% of Candriam SCA's portfolio in Q2 2026, its #108 holding.
Candriam SCA first reported a position in Mirum Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Candriam SCA's Mirum Pharmaceuticals position peaked at $45M in Q4 2025.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.